Introduction
Accumulating evidence from studies of many types of malignancies indicates that inflammatory signals regulated by cytokines and chemokines play critical roles in tumour progression (i.e. cancer cell proliferation, survival, angiogenesis and metastasis) (Coffelt et al., 2009) . Therefore, inflammation in the microenvironment may be considered the seventh hallmark of cancer in addition to the six classical hallmarks (Mantovani et al., 2008 (Mantovani et al., , 2009 . Although inflammation has long been suspected to be involved in brain tumour progression, direct evidence demonstrating its role in brain tumour pathology has been lacking.
The nine members of the interferon regulatory factor (IRF) family are transcription factors that play diverse roles in inflammatory responses including antiviral defence, cell proliferation and immune cell maturation (Honda et al., 2006) . In particular, IRF7, which is a master regulator of type I interferon-dependent immune responses (Honda et al., 2005) , was found to be over-expressed in paediatric lymphoma specimens (Park et al., 2007) . In addition, ectopic expression of IRF7 in immortal NIH 3T3 mouse embryonic fibroblasts leads to in vitro transformation and in vivo tumour formation (Zhang et al., 2004) .
Recently, several lines of evidence have suggested that the growth of glioblastoma multiforme is driven by glioma stem cells (GSCs) that display the molecular and cellular characteristics of normal neural stem cells. These shared properties include extensive self-renewal (i.e. continuous proliferation while maintaining an undifferentiated state) and a multi-differentiation potential (i.e. ability to produce a heterogeneous population of differentiated cells) (Stiles and Rowitch, 2008) . However, the signalling pathways governing GSC genesis and glioma progression are not well understood and are under intensive investigation.
The pleiotropic nature of inflammation regulated by cytokines and IRFs led us to hypothesize that certain IRFs over-expressed in brain tumours may function as modulators of glioma progression. Here we reveal that a novel inflammatory response mediated by the IRF7-interleukin 6 (IL6) signalling axis plays a crucial role in brain tumour progression by generating an inflammatory microenvironment that enables glioma cells to acquire GSC properties.
Materials and methods

Cell culture and reagents
Human BJ fibroblast cells, human glioma cell lines (A172, A1207, LN18, LN229, T98G, U87MG and U138MG), and primary human brain vascular endothelial cells were purchased from the American Type Culture Collection. Normal human astrocytes and neural stem cells were purchased from Cambrex Bio Science. Human BJ fibroblast cells, human glioma cell lines, normal human astrocytes and murine microglial cells were maintained in high-glucose Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum (HyClone), 1% penicillin and streptomycin (Life Technologies) and 2 mM L-glutamine (Life Technologies). Human brain vascular endothelial cells were grown in endothelial cell medium (Clonetics). All GSCs tested here were cultured using Neurobasal Õ medium (Invitrogen) supplemented with modified N2, B27, epidermal growth factor (20 ng/ml; R&D Systems) and basic fibroblast growth factor (20 ng/ml; R&D Systems) in suspension or in an adherent culture with laminin-coated flasks as described previously (Pollard et al., 2009) . Cells were treated with pyridone 6 (0.5 mM; Calbiochem; Pedranzini et al., 2006) , STAT3 inhibitor peptide (265 mM; Calbiochem; Turkson et al., 2001) and DAPT (100 nM; Sigma; Zheng et al., 2008) as indicated for 2 weeks to monitor tumoursphere-forming activity.
Proliferation assay
For cell proliferation, 2.5 Â 10 4 cells were plated in six-well dishes. The cells were harvested by trypsin digestion and counted using a haemocytometer on Days 1, 3 and 5.
Plasmids, short hairpin RNA construction and transduction
To generate IRF7-and IL6-overexpressing cell lines, glioma cells were transduced with pcDNA3.1-IRF7.1-puro, pcDNA3.1-IL6 and pcDNA3.1-puro (control) using Lipofectamine TM 2000 (Invitrogen). To generate gene knockdown cell lines, glioma cells were transfected with retroviral vectors that express short hairpin RNA (shRNA) against the target genes [pSUPER.retro-shScramble (control), pSUPER.retroshIRF7, pSUPER.retro-shIL6, pSUPER.retro-shCXCL1 and pSUPER. retro-shCCL2; OligoEngine]. GSCs were transduced with pSUPER.retro-shScramble and pSUPER.retro-shIRF7 using a microporation kit (Invitrogen). The target sequences were human IRF7-shRNA1
shRNA (5 0 -aaccacagttctacccct-3 0 ) and scramble shRNA (5 0 -agacgga ggcttacagtctgg-3 0 ).
RNA and protein analyses
Reverse transcriptase-polymerase chain reaction analyses were performed to determine messenger RNA levels. Total RNA was isolated from cells using TRIzol Õ reagent (Invitrogen) and transcribed using a complementary DNA synthesis kit (Fermentas) according to the manufacturers' instructions. For semi-quantitative reverse transcriptase-polymerase chain reaction, 1 ml complementary DNA was used to amplify IRF7, IL6, C-C motif chemokine 2 (CCL2), C-X-C motif chemokine 1 (CXCL1), 18S ribosomal RNA, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using gene-specific primer sets. Table 2 ). After removing the primary antibody, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. The signals were visualized by incubating the blots with enhanced chemiluminescence substrate (Pierce) and exposing to X-ray film (Agfa). Cytokines secreted into the cell culture media were quantified with an angiogenesis antibody array kit (RayBiotech), according to the manufacturer's instructions. The complete array maps (Array1) can be found at http:// www.raybiotech.com/map_all_m.asp#8. Secreted IL6 was quantified using a human IL6 enzyme-linked immunosorbent assay kit (R&D Systems). The array was scanned and the signal intensity was analysed using ImageJ software (http://rsb.info.nih.gov/ij/).
Immunofluorescence and immunohistochemistry assays
Human glioma specimens were collected from patients who had provided informed consent. The tissue collection protocol was approved by the institutional review board for human research at the Ajou University School of Medicine, Samsung Seoul Hospital and Sungkyunkwan University, Republic of Korea. Tumour tissue sections obtained from mouse xenografts and patients with glioma were incubated with IRF7, IL6, CD31, CD133, Nestin, S100b, Tuj1 and F4/80 antibodies. The stained sections were then examined using optical and confocal microscopy (Zeiss). Quantification of immunofluorescence staining was determined using MetaMorph Õ software (Molecular Devices). To quantify vessel areas in xenograft tumours driven by U87MG-puro, U87MG-IRF7, LN229-shScramble and LN229-shIRF7 Chromatin immunoprecipitation and luciferase reporter gene assays
The nuclear factor kappa B (NFB), IRF7 and IRF3 response elements on the CXCL1, IL6 and CCL2 promoters were selected according to the web-based information and results of a previous study (http://www. sabiosciences.com/chipqpcrsearch.php; Panne et al., 2007) . The chromatin immunoprecipitation assay (Upstate) was performed according to the manufacturer's protocol as described previously . Cells were fixed with 1% formaldehyde, suspended in sodium dodecyl sulphate lysis buffer and then sonicated. Immunoprecipitation was performed using antibodies against IRF7, IRF3, NFB and mouse IgG (Pierce). The eluted DNA was purified using the Qiagen polymerase chain reaction purification kit and analysed by semi-quantitative reverse transcriptase-polymerase chain reaction and quantitative real-time polymerase chain reaction. The primers used for chromatin immunoprecipitation, which amplify specific upstream regions of each promoter, are shown in Supplementary Table 3 . Promoter activity was determined in 293T cells after transfection of pGL3-IL6, pGL3-Jagged1 and pGL3-CSL promoter reporter plasmids using the Dual-Glo Luciferase Assay System (Promega). Transfection efficiency was determined by normalizing the reporter activity with Renilla luciferase activity according to the manufacturer's instructions (Promega).
In vitro tube formation assay
In vitro tube formation of human brain vascular endothelial cells was evaluated using an in vitro angiogenesis assay kit (Chemicon). The U87MG-puro-shScramble, U87MG-CXCL1-shScramble, U87MG-IL6-shScramble, U87MG-CCL2-shScramble, U87MG-IRF7-shScramble, U87MG-IRF7-shCXCL1, U87MG-IRF7-shIL6 and U87MG-IRF7-shCCL2 cells were seeded at 5 Â 10 5 cells per 10-cm plate. After 24-h incubation, the conditioned medium was harvested and filtered through a 0.2-mm filter (Sartorius Stedim Biotech). Endothelial cells were seeded in each well (1 Â 10 4 cells/well) and cultured in each type of conditioned medium at 37 C for 12 h. The cultures were then photographed ( Â 40 magnification). Three random view fields per well were examined, and the tubes were counted.
In vitro migration assay
Human brain vascular endothelial cells or microglial cells (3 Â 10 4 ) suspended in endothelial cell medium or starvation medium were added to the upper chamber (insert) of a migration chamber (3-mm pore size; Corning). The insert was then placed in a 24-well dish containing conditioned medium obtained from the indicated cell lines. The migrated cells were counted after 48 h.
Tumoursphere-forming assay
Cells were seeded in 12-well plates (200 cells/well) in Neurobasal Õ medium supplemented with N2, B27, epidermal growth factor and basic fibroblast growth factor. The epidermal growth factor and basic fibroblast growth factor were replaced every 3 days, and the number of tumourspheres was determined after 14 days. For the culture of three consecutive passages, tumourspheres were attached onto laminin-coated flasks and enzymatically dissociated between passages using Accutase Õ (Sigma).
Fluorescence-activated cell sorting analysis
To determine proportions of cells positive for CD133, Nestin, Sox2, GFAP, S100b, Tuj1 and NG2, the dissociated cells were fixed with 4% paraformaldehyde and then permeabilized with 0.1% saponin. The cells were incubated with anti-CD133, anti-Nestin, anti-Sox2, anti-GFAP, anti-S100b, anti-Tuj1 and anti-NG2 antibodies, followed by incubation with biotin-conjugated secondary antibody and phycoerythrin-conjugated avidin (BD Pharmingen). The stained cells were analysed by flow cytometry (FACSCalibur, BD). Cell viability after 24-h treatment with bis-chloroethylnitrosourea (100 mg/ml; Sigma-Aldrich), pyridone 6 (0.5 mM; Calbiochem), and DAPT (100 nM; Sigma) was determined by flow cytometry using cells double-stained with Annexin V-fluorescein isothiocyanate (1:100; BD Pharmingen) and propidium iodide (50 mg/ml; Sigma-Aldrich).
Bioinformatics analyses
The relative expression of IRFs was obtained from the Repository of Molecular Brain Neoplasia Data (REMBRANDT) database of the National Cancer Institute (http://caintegrator-info.nci.nih.gov/ rembrandt). Relative probe signals were converted into heatmaps with Heatmap Builder 1.1 software. The REMBRANDT database was also used to determine correlations between clinical characteristics, survival and gene expression in glioma specimens. In these data, the term 'all gliomas' indicates all specimens that were used to analyse patient survival. The 'High expression group 52.0 Â ' consisted of patients with gene expression 52-fold higher than mean values in normal tissue, whereas 'intermediate expression group' consisted of those with gene expression between that of 'high expression group 52.0Â ' and 'low expression group 42.0 Â '. In this study, the 'low expression group 42.0 Â ' consisted of only 21 patients, so we excluded this group from data analysis.
Mouse models
Nude mice (BALB/c nu/nu) were anaesthetized by intraperitoneal injection of a mixture of xylazine (Rompun; Bayer) and zolazepam (Zoletil 20; Virbac). For mouse brain orthotopic implantation, 5 Â 10 4 cells were stereotactically injected into the left striata (coordinates: anterior-posterior, + 2; medial-lateral, + 2; dorsal-ventral, À2 mm from bregma; n = 3). For subcutaneous cell implantation, 10 6 cells were subcutaneously injected into the mice (n = 4). For the mouse survival study, 1 Â 10 3 cells were orthotopically implanted into the mice (n = 6). A mouse model of wound healing was established as described previously (Hofer et al., 1998) with a minor modification. Nude mice were anaesthetized by intraperitoneal injection of a mixture of xylazine and zolazepam. After making a 2-cm incision, subcutaneous tissue and muscles were removed from the buttock of each mouse. Human glioma cells or rat C6 cells (1 Â 10 5 ) admixed with Matrigel TM were injected into the wound site, and the resulting tumours were collected after 11 weeks (for human glioma cells) or 19 days (for rat C6 cells). All mouse experiments were approved by the animal care committee at the College of Life Science and Biotechnology, Korea University, and were performed in accordance with government and institutional guidelines and regulations.
Statistics
Results of the multi-data set experiments were compared by analysis of variance using the Statistical Package for the Social Sciences software (version 12.0; SPSS); P 5 0.05 or P 5 0.01 were considered significant. Results of the two-data set experiments were compared by two-tailed Student's t-test; P 5 0.05 or P 5 0.01 was considered significant.
Results
Interferon regulatory factor 7 promotes brain tumours with increased angiogenesis and cell heterogeneity
To investigate the role of the inflammatory signalling in brain tumours, we first analysed the expression of the nine IRF family members (IRF1-IRF9) in different brain tumour types by mining the REMBRANDT database. Among the nine IRFs, IRF7, which is considered a master regulator of inflammation (Honda et al., 2005) , was over-expressed 43-fold (on average) in astrocytomas (n = 64) and glioblastomas (n = 152) compared with non-tumour tissues (n = 28) ( Supplementary Fig. 1A ). These findings suggest the involvement of IRF7 in brain tumour pathology. Additionally, IRF7 messenger RNA levels were elevated in A172 and LN229 glioma cell lines ( Supplementary Fig. 1B ).
To understand the tumorigenic role of IRF7, we generated U87MG cells over-expressing IRF7 (U87MG-IRF7) and IRF7-depleted LN229 cells (LN229-shIRF7) (Fig. 1A, inset) . IRF7 over-expression significantly increased tumour formation, whereas IRF7 knockdown markedly reduced tumorigenesis in subcutaneous xenograft models but did not significantly change cell growth in vitro ( Fig. 1A and B; Supplementary Fig. 1C ). Notably, CD31-positive vessel areas were substantially increased in U87MG-IRF7-driven tumours, whereas they were decreased in LN229-shIRF7-driven tumours (Fig. 1C) . This finding suggests that IRF7 accelerates tumorigenicity in part by inducing angiogenesis but not by activating proliferation. In contrast to U87MG-driven subcutaneous tumours consisting primarily of S100b + glioma cells, U87MG-IRF7-driven tumours consisted of various cell populations, including the less abundant Nestin + and CD133 + cells, as well as Tuj1 + glioma cells and S100b + glioma cells (Fig. 1D ), indicating tumour cell heterogeneity (Stiles and Rowitch, 2008; Shackleton et al., 2009) . We then examined whether IRF7 regulates resistance to chemotherapy such as bis-chloroethylnitrosourea treatment. We found that IRF7 over-expression in U87MG cells reduced bis-chloroethylnitrosourea-induced cell death, whereas IRF7 depletion in LN229 cells increased bis-chloroethylnitrosourea sensitivity ( Supplementary Fig. 1D ), implying that IRF7 may play a role in chemotherapy resistance in cancer cells.
Interferon regulatory factor 7 promotes angiogenesis and heterogeneity by inducing cytokine expression A custom angiogenesis antibody array was incubated with conditioned medium obtained from U87MG control cells and U87MG-IRF7 cells to identify the angiogenesis factors regulated by IRF7. We found that U87MG-IRF7 cells showed substantially increased secretion and messenger RNA levels of IL6, CXCL1 (Sager et al., 1992) and CCL2 (Deshmane et al., 2009 ) ( Fig. 2A and B; Supplementary Fig. 2A and B) . Since the IL6, CXCL1 and CCL2 promoters contain relatively conserved cis-elements for IRF7, NFB and IRF3 ( Supplementary Fig. 2C ), we performed a chromatin immunoprecipitation assay to determine their binding affinities. We found that IRF7 and NFB, but not IRF3, showed high binding affinities for their cognate sequences on the CXCL1 and CCL2 promoters, suggesting the regulation of CXCL1 and CCL2 transcription by both IRF7 and NFB in U87MG-IRF7 cells (Fig. 2C) . In contrast, IRF7 and IRF3 exhibited high binding affinities for their respective cognate sequences on the IL6 promoter, whereas NFB did not bind to the IL6 promoter, implying that IL6 transcription is regulated by IRF7 and IRF3 in U87MG-IRF7 cells (Fig. 2C) . Results from cell culture and xenograft experiments also demonstrated an increase in IL6 secretion and messenger RNA levels in U87MG-IRF7 cells and its reduction in IRF7-depleted LN229-shIRF7 cells ( Fig. 3A and B ; Supplementary Fig. 3A) . Finally, the results of luciferase reporter assays showed that IRF7 induced IL6 promoter activity in a dose-dependent manner ( Supplementary Fig. 3B ).
To investigate the role of IRF7 and its target cytokines in tumour angiogenesis, we performed in vitro migration and tube formation assays using the conditioned medium obtained from U87MG-puro-shScramble, U87MG-CXCL1-shScramble, U87MG-IL6-shScramble, U87MG-CCL2-shScramble, U87MG-IRF7 shScramble, U87MG-IRF7-shCXCL1, U87MG-IRF7-shIL6 and U87MG-IRF7-shCCL2 cell lines ( Supplementary Fig. 3C and D). We found that CXCL1 depletion in IRF7-overexpressing (Fig. 3C) , whereas IRF7 and its three target cytokines induced tube formation of human brain vascular endothelial cells (Fig. 3D ). Ectopic expression of IRF7 or IL6 in U87MG cells accelerated tumour formation in mouse brain and subcutaneous xenograft tumour models, whereas IL6 knockdown in U87MG-IRF7 cells dramatically suppressed tumour formation ( Fig. 4A and Supplementary Fig. 4) , indicating a crucial role for IL6 in IRF7-driven tumorigenesis. In addition, we observed microglia (F4/80 + ) infiltration of U87MG-IRF7-driven tumours but not U87MG-IL6-driven tumours (Fig. 4A ). Similar to in vivo microglia migration, microglia migration was enhanced by IRF7, CXCL1 and CCL2, but not IL6 (Fig. 4B) . Since U87MG-IRF7-driven tumours consisted of cell populations expressing stem cell markers as well as cell populations expressing markers of differentiation (Fig. 1D) , we examined whether the ectopic expression of IRF7 and IL6 in U87MG cells gives rise to GSC traits. We found that the tumoursphere-forming ability, a GSC feature (Singh et al., 2003; Vescovi et al., 2006) , was markedly increased in U87MG-IRF7 and U87MG-IL6 cells grown in neural stem cell culture conditions (Lee et al., 2006) (Fig. 4C) . Depletion of IL6 in U87MG-IRF7 cells led to the most significant decrease in tumoursphere formation (Fig. 4C) . Furthermore, GSC proportions (CD133 + , Nestin + and Sox2 + cells) increased with the over-expression of IRF7 and IL6 but decreased in the IL6-depleted U87MG-IRF7 cells ( Supplementary Fig. 5C ). We also found that the number of tumourspheres gradually increased in U87MG-IRF7 and to a lesser extent in U87MG-IL6 cells during three consecutive passages, indicating their self-renewal potential (Fig. 4D) . Taken together, these findings indicate that IRF7 promotes tumour progression and cancer stemness of glioma cells by inducing IL6, suggesting a more important role in cancers than previously reported (Rolhion et al., 2001) .
Interferon regulatory factor 7-interleukin 6 signalling confers cancer stemness to glioma cells through JAK-STAT-mediated activation of Jagged-Notch signalling
Our group and others have demonstrated that Notch signalling plays a crucial role in brain cancer stem cell genesis, and IL6 stimulates Janus kinase-signal transducer and activator of transcription (JAK-STAT3)-Notch signalling in breast cancer mammospheres (Sansone et al., 2007; Jeon et al., 2008) . Thus, we asked whether IRF7 induction of IL6 gives rise to brain cancer stem cell genesis through JAK-STAT3-mediated Notch activation. We suppressed the activation of JAK, STAT3 and Notch in U87MG-IRF7 and U87MG-IL6 cells using pharmacological inhibitors (JAK inhibitor pyridone 6, STAT3 inhibitor peptide, and DAPT, which indirectly inhibits Notch through -secretase inhibition). Our results showed that the tumoursphere-forming activity of U87MG-IRF7 and U87MG-IL6 cells was markedly suppressed by all three inhibitors (Fig. 5A ) but did not significantly change cell viability ( Supplementary Fig. 5A ). In addition short hairpin RNA-mediated knockdown of IL6 in U87MG-IRF7 cells reduced IL6 secretion ( Supplementary Fig. 3C ), levels of phosphorylated STAT3 and Jagged1, tumoursphere formation, and stem cell proportion ( Supplementary Fig. 5B-D) . Furthermore, results of luciferase reporter assays revealed that IRF7 dose-dependently stimulated Jagged1 and CSL/Notch promoter activities, which were partially suppressed after JAK inhibitor (pyridone 6) treatment ( Fig. 5B and  C) . The quantitative real-time polymerase chain reaction results showed that the increased messenger RNA levels of Jagged1 and two Notch-downstream targets (Hey1 and Hes1) (Iso et al., (Fig. 5D ), indicating that IRF7 confers cancer stemness to glioma cells by stimulating Jagged-Notch signalling through IL6-JAK/STAT signalling.
Interferon regulatory factor 7 expression in human patient-derived glioma stem cells and brain tumours
We further demonstrated the role of IRF7-IL6-Notch signalling in maintaining cancer stemness using several GSCs (X01, X02, X03, GSC3, GSC4 and GSC5) (Joo et al., 2008; Soeda et al., 2008) derived from patients with gliomas. IRF7 messenger RNA levels were strongly increased in all six GSCs compared with normal human astrocytes (Fig. 6A) , and the protein levels of IRF7, phosphorylated STAT3 and Jagged1 were also increased in X02, X03 and GSC4 cells (Fig. 6B) . Furthermore, inhibiting JAK/STAT-Notch signalling with pharmacological inhibitors (pyridone 6, STAT3 inhibitor and DAPT, respectively) sharply reduced the tumoursphere formation of X03, GSC4 and GSC8 cells (Fig. 6C) . We found that although IRF7 was not directly associated with cell proliferation, as judged by no consistent growth alterations in the IRF7-depleted X03 and GSC8 cells ( Supplementary Fig. 6A and B), IRF7 depletion significantly reduced IL6 and CCL2 expression (Fig. 6D) , inactivated STAT-Notch signalling (Fig 6E and Supplementary  Fig. 6C ), and suppressed tumoursphere formation (Fig. 6F) . Furthermore, IRF7 depletion in the GSCs led to a reduction in GSC proportion and GSC marker expression, but an increase in differentiated glioma cell proportion and differentiation lineage marker expression ( Fig. 6G and Supplementary Fig. 6D ), indicating that sustained IRF7 expression is necessary to prevent GSC differentiation.
To further assess the role of IL6 in IRF7-driven tumorigenesis in primary GSCs derived from patients with glioblastoma multiforme, we established GSC8-shIRF7-IL6 cells by transduction of IL6 in IRF7-depleted GSC8 cells (Supplementary Fig. 6E ). Orthotopic injection of GSC8-shScramble, GSC8-shIRF7 and GSC8-shIRF7-IL6 cells into nude mice showed that IRF7 depletion significantly prolonged survival in tumour-bearing mice, whereas the reconstitution of IL6 in the IRF7-depleted GSCs dramatically accelerated death (Fig. 6H) , indicating that IL6 signalling in the GSCs plays a crucial role in IRF7-driven tumorigenicity.
To identify upstream signals, we evaluated IRF7 expression in GSCs (GSC3, GSC4, X01 and X02) exposed to classic and putative glioma-related cytokines including epidermal growth factor, basic fibroblast growth factor, platelet-derived growth factor (Kesari and Stiles, 2006) , transforming growth factor (TGF)b (Penuelas et al., 2009) , leukaemia inhibitory factor (Penuelas et al., 2009 ), IL6, tumour necrosis factor (TNF), IL1b and lipopolysaccharide. We found that IRF7 expression was considerably increased in all these cell lines by TNF (Fig. 7A) . TNF is one of the best characterized inducers of inflammatory signal transduction (Locksley et al., 2001) and is secreted by astrocytes and microglial cells in pathological conditions affecting the brain (Chung and Benveniste, 1990; Bruce et al., 1996) . To investigate whether surgical wounds accelerate glioma progression through TNF-IRF7 signalling, we transplanted rat C6 glioma cells into a mouse wound healing model that exhibits a well-documented inflammatory microenvironment (Martin and Leibovich, 2005; Gurtner et al., 2008) and found that tumour growth was accelerated (Supplementary Fig.   7A ). Additionally, the increased TNF and macrophage infiltration observed in these tumours were associated with IRF7 induction (Supplementary Fig. 7B ). To further validate the biological effect of IRF7 on tumour progression in the inflammatory microenvironment, we subcutaneously transplanted LN229-shScramble and LN229-shIRF7 cells in wounded and non-wounded mice, and found that LN229-shScramble control cells, but not LN229-shIRF7 cells, markedly increased tumour formation in the wounded mice (Fig. 7B) . Immunofluorescence analysis revealed that TNF, IRF7, Jagged1, IL6, phosphorylated STAT3, Nestin and CD31 levels were substantially higher in LN229-shScramble-driven tumours than in LN229-shIRF7-driven tumours in the wounded mice ( Fig. 7C and D) . Furthermore, we found that IRF7 knockdown in the wounded mice decreased microglia infiltration (representative photos showing F4/80 + cells in Fig. 7C and quantitative data in Fig. 7E ) and GSC enrichment (representative photos showing CD133 + cells in Fig. 7C and quantitative data in Fig. 7F ). These findings suggest that IRF7 is regulated by the pathological inflammatory environment, and that TNF-IRF7 signalling may play a crucial role in glioma recurrence after surgery. To determine the clinical importance of IRF7 expression in human brain tumours, we analysed IRF7 expression and found that IRF7 messenger RNA and protein levels were strongly increased in high-grade gliomas (WHO grade IV; P 5 0.05) (Fig. 8A) . Furthermore, data obtained from the REMBRANDT database showed that a 2-fold increase in IRF7 expression (120 of 204 patients) correlated with poor survival in patients with gliomas ( Fig. 8B ; P 5 0.01). Interestingly, higher IRF7 expression was also significantly associated with patient clinical characteristics such as age (440 years), glioma grade (WHO grade IV), and clinical score (580% Karnofsky performance score), but not surgical resection (Table 1) . To further assess the relationship between IRF7 expression and patient clinical characteristics, we performed multivariate analysis using the Cox proportional hazards regression model. As shown in Table 2 , high IRF7 expression (hazard ratio 2.54; P = 0.014) and grade IV glioma (hazard ratio 3.28; P = 0.003) remained significant factors for poor survival after controlling for age, Karnofsky score and surgical resection, suggesting that IRF7 may serve as a prognostic factor for glioma patients.
In summary, we found that pathological inflammatory environments (e.g. surgical wounds) trigger IRF7 expression in gliomas through inflammatory cytokines (e.g. TNF), thereby promoting IL6, CXCL1 and CCL2 expression and secretion (Fig. 8C) . Secreted IL6 enables glioma cells to acquire GSC properties through JAK/STAT3-mediated activation of Jagged-Notch signalling, and stimulates tumour angiogenesis by inducing endothelial cell differentiation and vessel formation. Thus, the inflammatory microenvironment generated by TNF-IRF7-IL6 signalling in glioma cells plays a crucial role in disease progression and glioblastoma formation through induction of GSC genesis and angiogenesis.
Discussion
Interferon regulatory transcription factors appear to be important mediators of signals that sustain the inflammatory microenvironment necessary for tumour genesis and/or progression in many Although studies have demonstrated IRF7 over-expression in reactive hyperplastic lymph nodes, paediatric lymphoma and Epstein-Barr virus-transformed CNS lymphoma (Zhang et al., 2004; Park et al., 2007) , neither study demonstrates a functional link between IRF7 expression and tumorigenesis. On the other hand, several lines of evidence support the role of IL6 as a primary mediator of the inflammatory response important in the pathogenesis of many types of malignancies (Hodge et al., 2005; Rose-Jone et al., 2006) . Furthermore, recent studies have demonstrated the importance of IL6 in RAS-and epidermal growth factor receptor-mediated tumorigenesis, as well as the direct role of IL6-STAT signalling in an inflammatory model of de novo tumourigenesis (i.e. colitis-associated colon cancer) (Ancrile et al., 2006; Gao et al., 2007; Bollrath et al., 2009; Grivennikov et al., 2009) . Moreover, increased IL6 levels in gliomas are associated with the grade of malignancy and contribute to the maintenance of tumour heterogeneity through paracrine cytokine signalling circuits in U87MG-EGFRvIII cells (Rolhion et al., 2001 ; (12) 60 (12) P-value was obtained using Pearson's chi-squared test. These data sets were obtained from the REMBRANDT database. Tchirkov et al., 2007; Wang et al., 2009; Inda et al., 2010) . Our findings suggest that the overexpression of both IRF7 and IL6 in U87MG cells accelerates glioma formation by stimulating angiogenesis and Jagged/Notch-dependent acquisition of GSC properties.
Angiogenesis is a hallmark of cancer and the inflammatory response (Carmeliet and Jain, 2000; Hanahan and Weinberg, 2011 ). Recent studies have described a perivascular niche microenvironment in which endothelial-derived nitric oxide regulates the maintenance of GSC features through Notch signalling (Calabrese et al., 2007; Charles et al., 2010) . Therefore, our results strongly suggest that increased angiogenesis and activation of Notch signalling by IRF7-driven cytokines (IL6, CCL2 and CXCL1) play crucial roles in tumorigenicity and GSC genesis and maintenance. The upregulation of CCL2 and CXCL1 is also involved in GSC maintenance through recruitment of microglia, which further promotes the protumorigenic inflammatory microenvironment and angiogenesis by secreting additional angiogenic cytokines, such as TGFb, IL8 and RANTES (Ghosh and Chaudhuri, 2010) .
The difference between IRF7-and IL6-driven tumours is the infiltration of glioma cells into the brain parenchyma. Unlike tumours generated from U87MG-IRF7 cells, U87MG-IL6 cells give rise to gliomas with clear tumour margins in the brain. Given that recruitment of microglial cells in gliomas promotes tumour invasion and progression through membrane type I-matrix metalloproteinase expression, and CCL2 is involved in microglia cell migration (Markovic et al., 2009) , we speculate that the increased CCL2 and CXCL1 secretion demonstrated by U87MG-IRF7 cells, but not U87MG-IL6 cells, may play a role in the recruitment of microglial cells into the invasive edge of tumours, further stimulating the diffusive infiltration of tumour cells into the surrounding parenchymal tissue.
Developmental regulators such as Id4 and Olig2 appear to play direct roles in GSC genesis (Ligon et al., 2007; Jeon et al., 2008) . However, no studies have shown that inflammatory regulators are involved in GSC genesis and maintenance. The results reported here demonstrate that IRF7 is directly involved in promoting stem-like properties in glioma cells. Conversely, IRF7 depletion in GSCs diminishes self-renewal and increases differentiation. Similar to our previous study showing that Id4-induced activation of Jagged/Notch signalling is sufficient to convert Ink4a/Arf À /À astrocytes to glioma stem-like cells (Jeon et al., 2008) , the IRF7-driven acquisition and maintenance of GSC properties is also mediated by Jagged/Notch through IL6-JAK/STAT signalling. These findings suggest that deregulation of IRF7-IL6-Jagged/ Notch signalling may be an important event in tumour progression in many types of malignancies, including inflammation-associated cancers. Therefore, further investigation of this important signalling pathway in a variety of tumours will be particularly valuable for the development of new therapeutic agents and modalities.
